November 16, 2025 — Simcere Pharmaceutical Group (02096.HK) announced today that the National Medical Products Administration (NMPA) of China has approved the clinical trial application for SIM0712, an oral small-molecule degrader targeting STAT6 developed by Simcere, for the treatment of atopic dermatitis (AD).
SIM0712 is an oral small-molecule degrader targeting signal transducer and activator of transcription 6 (STAT6), developed using Simcere's proprietary PROTAC(Proteolysis Targeting Chimera)technology platform. By binding to the SH2 domain of STAT6, SIM0712 induces STAT6 protein degradation, thereby blocking interleukin-4 (IL-4)- and interleukin-13 (IL-13)-mediated signaling pathways and suppressing associated type 2 inflammatory responses.
Preclinical studies have demonstrated that SIM0712 effectively induces STAT6 protein degradation in various disease-relevant human immune and stromal cells at picomolar concentrations, with no significant degradation of other STAT family members (STAT1–STAT5) or CRBN substrates, indicating high potency and selectivity. Furthermore, SIM0712 has demonstrated significant anti-inflammatory efficacy in mouse models of atopic dermatitis and asthma. It has also exhibited favorable pharmacokinetic (PK) properties and a well-characterized pharmacokinetic/pharmacodynamic (PK/PD) relationship in rats, dogs, and cynomolgus monkeys, supporting its advancement into clinical development.
SIM0712 has the potential to address multiple type 2 inflammatory diseases, including atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE), and chronic rhinosinusitis with nasal polyps (CRSwNP), providing opportunities for development across multiple indications.
The clinical trial approval of SIM0712 further expands Simcere's self-developed pipeline in autoimmune and inflammatory diseases, reinforcing the company's commitment to addressing unmet medical needs through innovation.